These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 38524878)

  • 21. Pharmacological treatment of non-responders following bariatric surgery.
    Vinciguerra F; Romeo LM; Frittitta L; Baratta R
    Minerva Endocrinol (Torino); 2024 Jun; 49(2):196-204. PubMed ID: 33792233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy.
    Sarayani A; Donahoo WT; Hampp C; Brown JD; Winterstein AG
    Ann Intern Med; 2023 Apr; 176(4):443-454. PubMed ID: 36940443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.
    Ahmad NN; Robinson S; Kennedy-Martin T; Poon JL; Kan H
    Obes Rev; 2021 Nov; 22(11):e13326. PubMed ID: 34423889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and tolerability of new-generation anti-obesity medications: a narrative review.
    Patel DK; Stanford FC
    Postgrad Med; 2018 Mar; 130(2):173-182. PubMed ID: 29388462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
    Kelly EM; Tungol AA; Wesolowicz LA
    J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
    Milano W; De Biasio V; Di Munzio W; Foggia G; Capasso A
    Endocr Metab Immune Disord Drug Targets; 2020; 20(8):1232-1243. PubMed ID: 32410565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity.
    Mital S; Nguyen HV
    JAMA Netw Open; 2023 Oct; 6(10):e2336400. PubMed ID: 37824146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advancements in drug treatment of obesity.
    Carter R; Mouralidarane A; Ray S; Soeda J; Oben J
    Clin Med (Lond); 2012 Oct; 12(5):456-60. PubMed ID: 23101148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gender-related issues in the pharmacology of new anti-obesity drugs.
    Cataldi M; Muscogiuri G; Savastano S; Barrea L; Guida B; Taglialatela M; Colao A
    Obes Rev; 2019 Mar; 20(3):375-384. PubMed ID: 30589980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological Treatment for Obesity in Adults: An Umbrella Review.
    Khalil H; Ellwood L; Lord H; Fernandez R
    Ann Pharmacother; 2020 Jul; 54(7):691-705. PubMed ID: 31958967
    [No Abstract]   [Full Text] [Related]  

  • 31. Tolerability and safety of the new anti-obesity medications.
    Hainer V; Aldhoon-Hainerová I
    Drug Saf; 2014 Sep; 37(9):693-702. PubMed ID: 25096956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug treatment of obesity: current status and future prospects.
    Kakkar AK; Dahiya N
    Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment.
    Levi J; Wang J; Venter F; Hill A
    Obesity (Silver Spring); 2023 May; 31(5):1270-1279. PubMed ID: 36815242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapy of obesity: Available medications and drugs under investigation.
    Pilitsi E; Farr OM; Polyzos SA; Perakakis N; Nolen-Doerr E; Papathanasiou AE; Mantzoros CS
    Metabolism; 2019 Mar; 92():170-192. PubMed ID: 30391259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity Epidemic: Pharmaceutical Weight Loss.
    Curry SA
    R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current pharmacotherapies for obesity: A practical perspective.
    Golden A
    J Am Assoc Nurse Pract; 2017 Oct; 29(S1):S43-S52. PubMed ID: 29024552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.
    Samuels JM; Niswender KD; Roumie CL; Spann MD; Flynn CR; Ye F; Blankush J; Irlmeier R; Funk LM; Patel MB
    Diabetes Obes Metab; 2024 Sep; 26(9):3906-3913. PubMed ID: 38934217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.
    Polyzos SA; Goulis DG; Giouleme O; Germanidis GS; Goulas A
    Curr Obes Rep; 2022 Sep; 11(3):166-179. PubMed ID: 35501557
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.